Furthermore, the findings revealed that IDI2-AS1 had a stable association with the expression of PD1 (PDCD1) and PD-L1 (CD274) to serve as a potential prognostic marker or therapeutic targets of cancers integrated with m6A-related regulators (Supplementary Figure 7). Here, IDI2 is linked to cancer.